Compare CCCC & BKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCCC | BKT |
|---|---|---|
| Founded | 2015 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.3M | 245.7M |
| IPO Year | 2020 | N/A |
| Metric | CCCC | BKT |
|---|---|---|
| Price | $1.88 | $11.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.25 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 67.9K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.97% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,108,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $10.55 |
| 52 Week High | $4.26 | $12.92 |
| Indicator | CCCC | BKT |
|---|---|---|
| Relative Strength Index (RSI) | 32.78 | 47.83 |
| Support Level | $1.93 | $10.90 |
| Resistance Level | $2.13 | $11.10 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 0.00 | 50.00 |
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
Blackrock Income Trust Inc is a diversified investment fund with an investment objective to manage a portfolio of high-quality securities to achieve both preservations of capital and high monthly income. The trust seeks to achieve its investment objective by investing at least 65 percent of its assets in mortgage-backed securities. The Fund invests at least 80 percent of its assets in securities that are (i) issued or guaranteed by the U.S. government or one of its agencies or instrumentalities or (ii) rated at the time of investment either AAA by S&P Global Ratings (S&P) or Aaa by Moody's Investors Service, Inc (Moody's). The Fund may invest directly in such securities or synthetically through the use of derivatives.